Updates are available Correction dated 2023-02-08

Article History

Accepted: 6 December 2022

First Online: 18 January 2023

Change Date: 8 February 2023

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s11523-023-00947-9

Declarations

:

: AstraZeneca provided funding for medical writing support of this review in accordance with Good Publications Practice (GPP) guidelines (ExternalRef removed).

: S. Popat declares membership of the board of directors for the Mesothelioma Applied Research Foundation; consulting fees from Amgen, AstraZeneca, Bayer, BeiGene, Blueprint, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, GSK, Guardant Health, Incyte, Janssen, Merck KGaA, Roche, Takeda, Pfizer, Seattle Genetics, Turning Point Therapeutics, and Xcovery. M-J. Ahn declares participating in advisory councils or committees for Alpha Pharmaceutical, AstraZeneca, Bristol-Myers Squibb, MSD, Ono Pharmaceutical, Roche, and Takeda; receiving honoraria from AstraZeneca, Bristol-Myers Squibb, MSD, Ono Pharmaceutical, and Roche. S. Ekman declares an unrestricted grant from Boehringer Ingelheim for an investigator-initiated study; non-remunerated expert meetings sponsored by AbbVie, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, and Takeda; sponsoring of study to his institution by BMS. N.B. Leighl declares honoraria from Bristol-Myers Squibb and MSD; consulting fees from EMD Serono; and grants or funds from AstraZeneca and Bristol-Myers Squibb. S.S. Ramalingham declares participating in advisory councils or committees for Amgen, AstraZeneca, Bristol-Myers Squibb, Genentech, GSK, Merck, Tesaro, and Takeda; consulting fees from Amgen, AstraZeneca, Bristol-Myers Squibb, Genentech, Merck, Tesaro, and Takeda; and grants or funds, to his institution, from Amgen, Advaxis, AstraZeneca, Bristol-Myers Squibb, Genmab, Merck, Tesaro, and Takeda. T. Reungwetwattana declares honoraria from Amgen, AstraZeneca, Bristol-Myers Squibb, MSD, Novartis, Pfizer, Roche, Takeda, Yuhan, and Zuellig; advisory councils or committees for Amgen, AstraZeneca, Bristol-Myers Squibb, MSD, Pfizer, Roche, and Takeda; and grants or funds, to her institution, from AstraZeneca, Novartis, Pfizer, and Roche. S. Siva declares participating in an advisory council or committee for AstraZeneca; and honoraria from AstraZeneca. M. Tsuboi declares receiving lecture fees from Johnson & Johnson Japan, Teijin Pharma, Taiho Pharma, and Medtronic Japan; grant support, paid to his institution, lecture fees, and advisory board fees from AstraZeneca and Merck Sharp & Dohme; grant support, paid to his institution, and lecture fees from Eli Lilly Japan, Bristol-Myers Squibb, and Ono Pharmaceutical; lecture fees and advisory board fees from Chugai Pharmaceutical; grant support, paid to his institution, from Boehringer Ingelheim Japan; and grant support, paid to his institution, and advisory board fees from Novartis. Y-L. Wu declares honoraria from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly & Co., MSD, Pfizer Inc., Roche AG, and Sanofi; and grants or funds from AstraZeneca, Bristol-Myers Squibb, Pfizer Inc., and Roche AG. J.C-H. Yang declares advisory councils or committees for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck KGaA, MSD, Novartis, Ono Pharmaceuticals, Pfizer, Puma Technology, Roche/Genentech, Takeda Oncology, and Yuhan Pharmaceuticals; and grants or funds from AstraZeneca and Bayer.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca’s data sharing policy described at ExternalRef removed.

: Substantial contributions to the conception or design of the work: S. Popat, S. Ekman, N.B. Leighl, S.S. Ramalingham, T. Reungwetwattana, M. Tsuboi, Y-L. Wu, J.C-H. Yang. Substantial contributions to the acquisition, analysis, or interpretation of data for the work: S. Popat, M-J. Ahn, S. Ekman, S.S. Ramalingham, S. Siva, J.C-H. Yang. Drafting the work or revising it critically for important intellectual content: all authors. Final approval of the version to be published: all authors. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: all authors.